MicroRNA‑889‑3p targets FGFR2 to inhibit cervical cancer cell viability and invasion

Sun,Yu; Cheng,Yan; Zhang,Yan; Han,Kun

doi:10.3892/etm.2019.7675

MicroRNA‑889‑3p targets FGFR2 to inhibit cervical cancer cell viability and invasion

Authors:
- Yu Sun
- Yan Cheng
- Yan Zhang
- Kun Han
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: June 14, 2019 https://doi.org/10.3892/etm.2019.7675
Pages: 1440-1448

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are frequently dysregulated in cervical cancer, and the aberrant regulation of miRNAs may be involved in the regulation of various cancer‑associated biological processes. Therefore, further exploration of the specific roles of dysregulated miRNAs in cervical cancer and their associated mechanism may promote the development of effective therapeutic approaches. miRNA‑889‑3p (miR‑889) serves crucial roles in esophageal squamous cell carcinoma and hepatocellular carcinoma. However, to the best of our knowledge, no studies concerning the relationship between miR‑889 and cervical cancer were performed. The aims of this study were to measure miR‑889 expression in cervical cancer and to examine the potential effects of miR‑889 in cervical cancer development on a molecular level to provide potential clinical insight. The present study revealed that miR‑889 was downregulated in cervical cancer tissues and cell lines. Reduced miR‑889 expression was significantly associated with International Federation of Gynecology and Obstetrics cancer staging and with lymph node metastasis. In addition, miR‑889 overexpression reduced cervical cancer cell viability and invasive ability. Using bioinformatics analysis, fibroblast growth factor receptor 2 (FGFR2) was predicted to be a potential target of miR‑889, which was confirmed using luciferase reporter assay. Reverse transcription‑quantitative PCR and western blot analysis results suggested that miR‑889 overexpression decreased FGFR2 expression in cervical cancer cells at the mRNA and the protein level, respectively. Conversely, FGFR2 silencing using small interfering RNA imitated the tumor suppressive effects of miR‑889 overexpression in cervical cancer cells, which was successfully reversed by plasmid‑facilitated FGFR2 overexpression. These observations demonstrated that miR‑889 may serve tumor suppressive roles in cervical cancer by directly targeting FGFR2, which indicated that this miRNA may be a promising therapeutic target for patients with cervical cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Castellsague X: Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 110 (3 Suppl 2). S4–S7. 2008. View Article : Google Scholar
4	Du CX and Wang Y: Expression of P-Akt, NFkappaB and their correlation with human papillomavirus infection in cervical carcinoma. Eur J Gynaecol Oncol. 33:274–277. 2012.PubMed/NCBI
5	Ghebre RG, Grover S, Xu MJ, Chuang LT and Simonds H: Cervical cancer control in HIV-infected women: Past, present and future. Gynecol Oncol Rep. 21:101–108. 2017. View Article : Google Scholar : PubMed/NCBI
6	Hildesheim A and Wang SS: Host and viral genetics and risk of cervical cancer: A review. Virus Res. 89:229–240. 2002. View Article : Google Scholar : PubMed/NCBI
7	Link A and Kupcinskas J: MicroRNAs as non-invasive diagnostic biomarkers for gastric cancer: Current insights and future perspectives. World J Gastroenterol. 24:3313–3329. 2018. View Article : Google Scholar : PubMed/NCBI
8	To KK, Tong CW, Wu M and Cho WC: MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside. World J Gastroenterol. 24:2949–2973. 2018. View Article : Google Scholar : PubMed/NCBI
9	Wang F, Li B and Xie X: The roles and clinical significance of microRNAs in cervical cancer. Histol Histopathol. 31:131–139. 2016.PubMed/NCBI
10	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
11	He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
12	Kozomara A and Griffiths-Jones S: miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42:D68–D73. 2014. View Article : Google Scholar : PubMed/NCBI
13	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
14	Laengsri V, Kerdpin U, Plabplueng C, Treeratanapiboon L and Nuchnoi P: Cervical Cancer Markers: Epigenetics and microRNAs. Lab Med. 49:97–111. 2018. View Article : Google Scholar : PubMed/NCBI
15	Zhu B, Ju S, Chu H, Shen X, Zhang Y, Luo X and Cong H: The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma. Oncol Lett. 15:6094–6106. 2018.PubMed/NCBI
16	Lu J, Zhan Y, Feng J, Luo J and Fan S: MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sci. 14:390–397. 2018. View Article : Google Scholar : PubMed/NCBI
17	Cai N, Hu L, Xie Y, Gao JH, Zhai W, Wang L, Jin QJ, Qin CY and Qiang R: MiR-17-5p promotes cervical cancer cell proliferation and metastasis by targeting transforming growth factor-beta receptor 2. Eur Rev Med Pharmacol Sci. 22:1899–1906. 2018.PubMed/NCBI
18	Li GC, Cao XY, Li YN, Qiu YY, Li YN, Liu XJ and Sun XX: MicroRNA-374b inhibits cervical cancer cell proliferation and induces apoptosis through the p38/ERK signaling pathway by binding to JAM-2. J Cell Physiol. 233:7379–7390. 2018. View Article : Google Scholar : PubMed/NCBI
19	Sanches JGP, Xu Y, Yabasin IB, Li M, Lu Y, Xiu X, Wang L, Mao L, Shen J, Wang B, et al: miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD. Chem Biol Interact. 285:85–95. 2018. View Article : Google Scholar : PubMed/NCBI
20	Xu Y, He J, Wang Y, Zhu X, Pan Q, Xie Q and Sun F: miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP. FEBS Lett. 589:1127–1135. 2015. View Article : Google Scholar : PubMed/NCBI
21	Xie H, Zhang Q, Zhou H, Zhou J, Zhang J, Jiang Y, Wang J, Meng X, Zeng L and Jiang X: microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells. Cytotechnology. 70:513–521. 2018. View Article : Google Scholar : PubMed/NCBI
22	Cha Y, Kim HP, Lim Y, Han SW, Song SH and Kim TY: FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro. Mol Oncol. 12:993–1003. 2018. View Article : Google Scholar : PubMed/NCBI
23	Fu YT, Zheng HB, Zhang DQ, Zhou L and Sun H: MicroRNA-1266 suppresses papillary thyroid carcinoma cell metastasis and growth via targeting FGFR2. Eur Rev Med Pharmacol Sci. 22:3430–3438. 2018.PubMed/NCBI
24	Marzioni D, Lorenzi T, Mazzucchelli R, Capparuccia L, Morroni M, Fiorini R, Bracalenti C, Catalano A, David G, Castellucci M, et al: Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int J Immunopathol Pharmacol. 22:627–638. 2009. View Article : Google Scholar : PubMed/NCBI
25	Lei H and Deng CX: Fibroblast growth factor receptor 2 signaling in breast cancer. Int J Biol Sci. 13:1163–1171. 2017. View Article : Google Scholar : PubMed/NCBI
26	Choi CH, Chung JY, Kim JH, Kim BG and Hewitt SM: Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients. J Transl Med. 14:1242016. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Kawase R, Ishiwata T, Matsuda Y, Onda M, Kudo M, Takeshita T and Naito Z: Expression of fibroblast growth factor receptor 2 IIIc in human uterine cervical intraepithelial neoplasia and cervical cancer. Int J Oncol. 36:331–340. 2010.PubMed/NCBI
29	Li M, Qian Z, Ma X, Lin X, You Y, Li Y, Chen T and Jiang H: MiR-628-5p decreases the tumorigenicity of epithelial ovarian cancer cells by targeting at FGFR2. Biochem Biophys Res Commun. 495:2085–2091. 2018. View Article : Google Scholar : PubMed/NCBI
30	Yang X, Ruan H, Hu X, Cao A and Song L: miR-381-3p suppresses the proliferation of oral squamous cell carcinoma cells by directly targeting FGFR2. Am J Cancer Res. 7:913–922. 2017.PubMed/NCBI
31	Wang JY and Chen LJ: The role of miRNAs in the invasion and metastasis of cervical cancer. Biosci Rep. 39:2019.
32	Pedroza-Torres A, Lopez-Urrutia E, Garcia-Castillo V, Jacobo-Herrera N, Herrera LA, Peralta-Zaragoza O, López-Camarillo C, De Leon DC, Fernández-Retana J, Cerna-Cortés JF and Pérez-Plasencia C: MicroRNAs in cervical cancer: Evidences for a miRNA profile deregulated by HPV and its impact on radio-resistance. Molecules. 19:6263–6281. 2014. View Article : Google Scholar : PubMed/NCBI
33	Banno K, Iida M, Yanokura M, Kisu I, Iwata T, Tominaga E, Tanaka K and Aoki D: MicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatment. TheScientificWorldJournal. 2014:1780752014. View Article : Google Scholar : PubMed/NCBI
34	Shishodia G, Verma G, Das BC and Bharti AC: miRNA as viral transcription tuners in HPV-mediated cervical carcinogenesis. Front Biosci (Schol Ed). 10:21–47. 2018. View Article : Google Scholar : PubMed/NCBI
35	Katoh Y and Katoh M: FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). Int J Mol Med. 23:626–639. 2018.
36	Ishiwata T: Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells. Front Biosci (Landmark Ed). 23:626–639. 2018. View Article : Google Scholar : PubMed/NCBI